Current Funding Opportunities:

Sponsor: Massachusetts General Hospital Sean M. Healey & AMG Center for ALSDescription: The Healey Center International Prize for Innovation in ALS is an annual global prize celebrating excellence in research for an individual or team who catalyze exceptional discoveries leading to a transformative advance in therapy development in ALS. The award is $50,000 USD and travel reimbursement up to $2,500 USD to attend the 2019 International Symposium on ALS/MND in Perth, Australia.Deadline: Nominations due by July 9, 2019.

Sponsor: ADDF and AFTDDescription: Through this program, the Association for FTD, in partnership with the Alzheimer’s Drug Discovery Foundation (ADDF), seeks to advance and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs. Current funding priorities for this program include: (1) Lead optimization of novel disease-modifying compounds (e.g., medicinal chemistry refinement, in vitro ADME) and (2) Testing of novel compounds, biologics, or repurposed drugs in relevant animal models (e.g., in vivo pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, preliminary rodent tolerability studies). The award is $100,000 – $150,000 USD for 1 year with the possibility of renewal.Deadline: Application due by July 12, 2019.

Sponsor: AriSLADescription: These grants concern research projects with a solid background and consistent preliminary data. The duration of the proposed project is 12-36 months and must be based in Italy. Up to €80,000 will be awarded.Deadline: Application due by May 28, 2019.

Sponsor: AriSLADescription: These grants concern basic and preclinical research projects with highly innovative and original hypotheses, where preliminary data are either not available or to be consolidated. As such, they are intended to collect or strengthen preliminary data for subsequent larger scale funding. Particularly for this type of application, AriSLA Foundation encourages applications from junior investigators and investigators who are new to the ALS field. The duration of the proposed project is 12 months and must be based in Italy. Up to € 60,000 will be awarded.Deadline: Application due by May 28, 2019.

Sponsor: Muscular Dystrophy AssociationDescription: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.Deadline: Letter of Intent due by June 1, 2019.

Sponsor: ALS CanadaDescription: The purpose of the program is to invest in the best possible projects that are i) novel research approaches, supported by sound rationale and a feasible experimental plan, but not necessarily preliminary data, ii) part of an ongoing ALS research program, and aimed toward the vision of ALS Canada, which is “A future without ALS” or iii) research focused on avenues to maximize function, minimize disability and optimize quality of life through symptom management, and support to families and persons or families living with ALS. Up to eight awards of up to $100,000 will be awarded.Deadline: Application due by June 7, 2019.

Sponsor: Multiple Funding AgenciesDescription: The Medical Research Council (MRC) in the UK in collaboration with the National Science Foundation of the United States, Canadian Institutes of Health Research (CIHR) of Canada, Fonds de Recherche du Quebec (FRQ) of Quebec, and Deutsche Forschungsgemeinschaft (DFG) of Germany are pleased to invite proposals for NeuroNex. This initiative will provide funding for high-quality UK-based research projects focused on addressing grand challenges in neuroscience as part of larger networks with international groups.Deadline: Application due by June 14, 2019.

Sponsor: NINDSDescription: This funding opportunity announcement invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials.Deadline: Letter of Intent due by July 14, 2019.

Sponsor: Bruno and Ilse Frick Foundation for Research on ALSDescription: This aim of this award is to support early-career ALS scientists by providing funding for their basic research. Scientists across the globe are encouraged to apply! The funding is 100,000 CHF over 2 years. Deadline: Application due by September 30, 2019.

Sponsor: Motor Neurone Disease AssociationDescription: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Applications will begin to be accepted on September 6, 2019. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute. Deadline: Application due by October 25, 2019.

Sponsor: California Institute of Regenerative Medicine (CIRM)Description: The objective of this program announcement is to create a highly competitive
partnering opportunity to accelerate the completion an IND or IDE filing with the FDA and initiate clinical trial start-up with a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $6M USD. CIRM expects projects under this program to advance rapidly into the clinic and to achieve the proposed IND filing within 18 months.Deadline: Applications due by 2PM PST on the last business day of each month.

Sponsor: California Institute of Regenerative Medicine (CIRM)Description: The objective of this program announcement is to create a highly competitive
partnering opportunity to accelerate the completion of a clinical trial for a promising
stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $10-15M USD.Deadline: Applications due by 2PM PST on the last business day of each month.

Sponsor: California Institute of Regenerative Medicine (CIRM)Description: The objective of this program announcement is to support new activities on active
CIRM-funded clinical trial projects that will directly enable product registration with the
Food and Drug Administration (FDA). This award is only available to holders of a
current CLIN2 award for a trial that has been deemed by FDA to be sufficient for
registration.Deadline: Applications due by 2PM PST on the the last business day of each month.

Sponsor: Rare Diseases Models and Mechanisms NetworkDescription: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution. Deadline: Applications will be accepted on a rolling basis.

Sponsor: Dana FoundationDescription: This grant funds "first-in-man" clinical studies of therapies being developed for brain diseases. Funded studies can receive up to $300,000 payable over three years. Potential applicants may submit a preliminary proposal and budget to determine full proposal eligibility. Applications are not solely restricted to clinical research scientists based in the United States.Deadline: Applications are accepted on a rolling basis.

Sponsor: Weston Brain InstituteDescription: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years. Deadline: Applications are accepted on a rolling basis.

Sponsor: Alzheimer's Drug Discovery FoundationDescription: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.Deadline: Applications are accepted on a rolling basis.

Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.Deadline: Applications are accepted on a rolling basis.

Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.Deadline: Varies, see individual program for details.